Having now identified the market size for long-acting injectable schizophrenia drugs, forecast out into the future, uh, for Europe, we can now turn our attention to RO V and how much revenue and profit we might expect RO V to make from sales of this drug.

So the first place that we're gonna start with is the Doria market share.

Again, coming from management expectations, there is a 1% expected market share in Europe in 2021 growing to a 7.5% market share during 2026.

Now, what we want to do is to see this market share grow linearly.

So we're going to need a quick formula to achieve that for us.

I'm gonna start in 2025.

I'm gonna work down from the maximum market share of 7.5%.

I'm gonna deduct from that the difference between peak market share 7.5 and the 1% market share.

I'm gonna lock onto the 1% market share because I'm gonna copy this formula back to 2022 to 2024 in a second, okay? But that difference is gonna have grown linearly over the five year growth period.

So we need to divide this by the number of columns that we have, using the columns function from our row J through to row N in this example.

So that's five columns.

So if we're counting the number of columns that'll give us five, we're taking the 6.5% increase in our market share, dividing it by five.

That will give us one year's worth of growth that we're taking away from 7.5.

Okay? We do just need to be careful to lock onto J 37 in both parts of the formula, but then once we've got that formula, we can copy it and paste it into the previous three columns to get this linear growth in the market share.

From 2021 up to 2025.

After we get to 2026, the maximum market share, we're going to assume that we get a decline in market share of 10% per year.

So it's gonna take that 7.5% and multiply it by 0.9 to get a 10% decline in market share. Thereafter, we can now go back to think about how much revenue we're gonna be making as Roe V from selling this Doria product into the future.

And the thing we've gotta be careful with here is that there is an expectation that there will be some sales made on a direct basis.

70% of our sales made directly.

This involves Roe V manufacturing and selling Doria itself directly to uh, medical practitioners.

The alternative to this is our indirect sales.

And for indirect sales, Roe V is going to be selling a license to another pharmaceutical company to allow them to produce and sell this product.

And on those indirect sales, RO V is only gonna be Earning a royalty fee.

So let's first of all calculate the sales that we're gonna make on Doria.

So the market size, we think in 2021, the first year when we're gonna be allowed to sell Doria the 1,480 thousands of Euros, we multiply that by the market share that we have of 1%, but then we need to say, well, of that market share, we've really gotta be careful with our units because we're now looking at things from a Roe V perspective.

And Roe V looks at its financial statements in thousands of euros, but the market size was identified in millions of euros.

So we need to take this sale amount and multiply it by 1000 to transform it from a millions of Euros into a thousands of euros. That will then match with the other numbers that we already have, that our revenues tab and our income statements tab.

This is not all the revenue to Doria, though.

Some of these sales are made on an indirect basis for which we as Ro v do not receive all of the revenue.

So we need to split this down between sales made on a direct basis.

Okay? So take all of the sales of which 70% are gonna be made on a direct basis, and then the indirect sales must be the difference.

So what we've now calculated is the sales of Doria.

So if we want to calculate the revenues that we are earning as RO V, well we are making all of the revenue on the direct sales.

That is all revenue for us as Roe V, but on the indirect sales, we are only earning the royalty fee of 20%.

So as a result, the total revenue that Roe v's gonna be earning from sales of Doria in 2021 in Europe, we'll come through to this 11.4 million euros.